JEFFERIES GLOBAL HEALTHCARE CONFERENCE IN LONDON - DENALI THERAPEUTICS INC
Explicit Guidance:
- Revenue: Provided quarterly revenue guidance for 2026 only, specifically expecting Q4 2026 revenue of $30–32 million. No explicit guidance disclosed for 2027.
- Market Potential: Expects Avalya revenues to exceed current standard of care (Elaprase) worldwide (projected >$700M) upon full market penetration.
- Pricing: U.S. annual price for a 30kg patient is approx. $800,000, representing a 60% premium over the incumbent ERT ($500,000).
- Patient Populations: Total U.S. Hunter Syndrome population ~500 (current label eligible 375, ~75%); Worldwide population ~1,500 (one-third Europe, one-third outside Europe, one-third other).
Business-Segment Outlook:
- Avalya (Hunter Syndrome): Goal to become market leader by treating all new patients and switching prevalent patients from existing ERT. Key milestones include label expansion to adults (25% of population, >30% value due to weight-based dosing) and international market access.
- Sanfilippo (MPS III): Filing BLA next year (2026) using data from the Phase 1/2 cohort. Expect full data readout at World Congress in February 2027 (20-patient dataset). Confirmatory Phase 3 study (Zafi) enrollment has begun.
- Progranulin (FTD): Data readout scheduled for first half of 2027. Treatment duration extended from 6 to 12 months to measure proximal (lysosomal) and distal (neurofilament) biomarkers.
- Alzheimer's (Tau & A-Beta):
- Tau (DNL921): Seeking to identify the right dose and achieve robust CSF tau reduction in 2027, anticipating efficacy studies to follow. Aiming for 45% or less tau reduction (vs. Biogen's lower doses) to drive clinical benefit.
- Amyloid (DNL921): Healthy volunteer data to assess hematology/tolerability (on/off switch mechanism) occurring immediately. Early biomarker data for plaque reduction in Alzheimer's patients expected in 2027.
- Pompe & Granulin: Noting "important readouts" in Pompe and FTD granulin portfolios, with specific focus on Alzheimer's portfolio data continuing to emerge.
Market and Competitive Outlook:
- Competitive Landscape: Anticipates capturing the entirety of the Elaprase market share and more, driven by superior brain penetration, biomarker normalization, and tolerability.
- Regulatory Shifts: Acknowledges a shifting FDA bar due to the approval of Ultragenyx's gene therapy (based on natural history), necessitating potential design adjustments for Denali's Sanfilippo confirmatory study (moving from head-to-head to baseline comparison).
- Pricing Strategy: Expectation that international expansion requires overcoming pricing/reimbursement hurdles following regulatory approval; COMPAS study results expected to facilitate adult approvals in the U.S. and Europe, while other regions may leverage accelerated pathways based on U.S. data.
Macro / Industry Outlook:
- Regulatory Environment: Active engagement with FDA (CDER and CBER) regarding accelerated approval pathways, particularly for rare diseases where historical data comparators are now permissible.
- Technology Trends: Confidence in the "transport vehicle" platform's ability to achieve even distribution throughout the CNS (unlike intrathecal delivery), which is viewed as critical for clinical benefit in Alzheimer's and FTD.
- Pricing & Access: Weight-based dosing is a critical value lever, especially for adult populations who constitute a disproportionate share of the total treatment value.
Strategic Initiatives:
- Pipeline Expansion: Leveraging the validated transport vehicle platform to expand from Hunter Syndrome into Sanfilippo, FTD, and Alzheimer's (Tau/Amyloid).
- Clinical Trial Design:
- COMPAS Study: Head-to-head with Elaprase; completion of two-year endpoint expected end of 2026, with readout anticipated in 2028. Focus on neurologic (Vineland) and somatic endpoints in ages 2–6 and adult cohorts.
- Alzheimer's Tau: Moving to multi-dose studies in actual Alzheimer's patients to assess tau reduction and biomarker normalization.
- Alzheimer's A-Beta: Developing an "on-off switch" antibody integrated with TFR binding to improve tolerability and enable sub-Q dosing (future goal).
- Route of Administration: Strategic focus on transitioning to sub-Q dosing for future products (Avalya and Alzheimer's assets) to facilitate prevention settings.
Risks and Headwinds to Outlook:
- Regulatory Uncertainty: The "bar" for efficacy may be shifting due to gene therapy approvals; success of accelerated approval for FTD and Alzheimer's depends on convincing FDA of the link between biomarker reduction (NFL, tau) and clinical benefit.
- Enrollment Challenges: Sanfilippo Phase 3 enrollment timelines depend on patient availability and the competitive landscape (gene therapy approvals).
- Data Interpretation: Heterogeneity in patient mutations and disease progression (especially in Sanfilippo and Hunter) complicates power calculations and outcome expectations.
- Pricing/Reimbursement: International market access is contingent on securing pricing and reimbursement quickly after regulatory approval.
- Timing: Delays in COMPAS readout or Sanfilippo Phase 3 enrollment could push commercialization timelines beyond current expectations.
Management Tone on the Future:
- Confidence: Highly confident ("very confident," "exciting time") in the platform's ability to validate itself via Avalya and translate to the broader pipeline.
- Momentum: Describes the launch as "better than internally expected" with "overwhelming" community feedback.
- Urgency: Expresses a "sense of urgency" regarding the launch expansion and the COMPAS study completion.
- Caveats: Explicitly hedges on 2027 guidance, stating the company has "not yet disclosed how we will approach 2027" to maintain flexibility based on 2026 trajectory.
Miscellaneous:
- Biomarkers: Key biomarkers identified include CSF heparin sulfate (Hunter/Sanfilippo), neurofilament light chain (NFL) (neurodegeneration marker in FTD/Alzheimer's), glucosylsphingosine (lysosomal function), and GM3.
- Clinical Endpoints: Vineland (behavioral) for Hunter; Bailey (cognitive) for Sanfilippo; NFL reduction as a primary predictor for accelerated approval in FTD/Alzheimer's.
- Study Specifics: COMPAS study includes 65 patients across two cohorts; Sanfilippo Phase 2 included 20 patients (8 dose-finding + 12 marketed dose).
- Company
- DENALI THERAPEUTICS INC
- Keywords
- DENALI THERAPEUTICS INC